WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients ...

Both acute and long-term colchicine use to treat patients with acute myocardial infarction (MI) did not reduce cardiovascular death, myocardial infarction, stroke or ischemia-driven revascularization, ...